Ebola clinical activity speeds up with vaccine candidates in works

The Ebola outbreak has taught us that the health systems in West Africa are under-resourced and vulnerable. Scaling up capability of local healthcare provision is an important consideration for control of this virus, and drug-makers are gearing up to expedite development of Ebola vaccines. » Read about vaccines in development

FDA approves Obizur for acquired hemophilia A

FDA has approved Antihemophilic Factor (Recombinant), Porcine Sequence] (Obizur, Baxter) for the treatment of bleeding episodes in adults with acquired hemophilia A. » Read more about this rare, life-threatening bleeding disorder

Continuing Education

Motivational interviewing techniques for chronic disease management: Focus on cardiovascular disease

This month's CE activity is part of a year-long CPE series, Medication Therapy Management Considerations for Adult Patients with Cardiovascular Disease. From February 2014 through January 2015, pharmacists can earn up to 24 hours of CPE credit with 12 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to educate pharmacists, particularly in the outpatient setting, regarding the clinical principles, techniques, and benefits of using motivational interviewing to improve cardiovascular outcomes in their patients.

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exam and earn up to 2 CPE credits, click here to log in with the session code 14DT11-YXJ69.

Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

FDA: Keep boxed warning on Chantix

An FDA advisory committee has voted to keep the boxed warning for varenicline (Chantix, Pfizer) that states that the drug may cause serious neuropsychiatric events. » Read more

• 5 ways formulary managers can brace for Ebola

• FDA approves first long-acting recombinant coagulation Factor IX concentrate for patients with Hemophilia B

RESOURCES

Latest Clinical News